71 related articles for article (PubMed ID: 10918951)
21. Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study.
Busse W; Levine B; Andriano K; Lavecchia C; Yegen U
Clin Ther; 2004 Oct; 26(10):1587-98. PubMed ID: 15598475
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of fluticasone and formoterol in a single pressurized metered dose inhaler.
Bodzenta-Lukaszyk A; Pulka G; Dymek A; Bumbacea D; McIver T; Schwab B; Mansikka H
Respir Med; 2011 May; 105(5):674-82. PubMed ID: 21196104
[TBL] [Abstract][Full Text] [Related]
23. Total reversibility testing as indicator of the clinical efficacy of formoterol in COPD.
Molimard M; Bourcereau J; Le Gros V; Bourdeix I
Respir Med; 2005 Jun; 99(6):695-702. PubMed ID: 15878485
[TBL] [Abstract][Full Text] [Related]
24. Improvement of asthma therapy by a novel formoterol multidose dry powder inhaler.
Moeller M; Grimmbacher S; Munzel U
Arzneimittelforschung; 2008; 58(4):168-73. PubMed ID: 18540478
[TBL] [Abstract][Full Text] [Related]
25. [Bronchial asthma treated with long-acting beta 2 agonist. Comparison between formoterol (12 mu/g) inhaled twice daily and salbutamol (200 mu/g) inhaled 4 times daily].
Sprogøe-Jakobsen U; Viktrup L; Davidsen O; Viskum K
Ugeskr Laeger; 1992 Nov; 154(47):3325-8. PubMed ID: 1361083
[TBL] [Abstract][Full Text] [Related]
26. Formoterol concentrations in blood and urine: the World Anti-Doping Agency 2012 regulations.
Eibye K; Elers J; Pedersen L; Henninge J; Hemmersbach P; Dalhoff K; Backer V
Med Sci Sports Exerc; 2013 Jan; 45(1):16-22. PubMed ID: 22843108
[TBL] [Abstract][Full Text] [Related]
27. Bioequivalence studies of film-coated tablet and chewable tablet generic formulations of montelukast in healthy volunteers.
Cánovas M; Arcabell M; Martínez G; Canals M; Cabré F
Arzneimittelforschung; 2011; 61(11):610-6. PubMed ID: 22232849
[TBL] [Abstract][Full Text] [Related]
28. Cumulative high doses of inhaled formoterol have less systemic effects in asthmatic children 6-11 years-old than cumulative high doses of inhaled terbutaline.
Kaae R; Agertoft L; Pedersen S; Nordvall SL; Pedroletti C; Bengtsson T; Johannes-Hellberg I; Rosenborg J
Br J Clin Pharmacol; 2004 Oct; 58(4):411-8. PubMed ID: 15373934
[TBL] [Abstract][Full Text] [Related]
29. A 3-month comparison of formoterol with terbutaline via turbuhaler. A placebo-controlled study.
Ekström T; Ringdal N; Tukiainen P; Runnerström E; Soliman S
Ann Allergy Asthma Immunol; 1998 Sep; 81(3):225-30. PubMed ID: 9759798
[TBL] [Abstract][Full Text] [Related]
30. Clinically equivalent bronchodilatation achieved with formoterol delivered via Easyhaler and Aerolizer.
Dubakiene R; Nargela R; Sakalauskas R; Vahteristo M; Silvasti M; Lähelmä S
Respiration; 2006; 73(4):441-8. PubMed ID: 16432294
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of budesonide and formoterol administered via 1 pressurized metered-dose inhaler in patients with asthma and COPD.
Tronde A; Gillen M; Borgström L; Lötvall J; Ankerst J
J Clin Pharmacol; 2008 Nov; 48(11):1300-8. PubMed ID: 18974284
[TBL] [Abstract][Full Text] [Related]
32. Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease.
Rosenkranz B; Rouzier R; Kruse M; Dobson C; Ayre G; Horowitz A; Fitoussi S
Respir Med; 2006 Apr; 100(4):666-72. PubMed ID: 16303295
[TBL] [Abstract][Full Text] [Related]
33. Inhaled steroid/long-acting beta 2 agonist combination products provide 24 hours improvement in lung function in adult asthmatic patients.
Lötvall J; Langley S; Woodcock A
Respir Res; 2006 Aug; 7(1):110. PubMed ID: 16919161
[TBL] [Abstract][Full Text] [Related]
34. The pulmonary and extra-pulmonary effects of high-dose formoterol in COPD: a comparison with salbutamol.
Goldkorn A; Diotto P; Burgess C; Weatherall M; Holt S; Beasley R; Siebers R
Respirology; 2004 Mar; 9(1):102-8. PubMed ID: 14982610
[TBL] [Abstract][Full Text] [Related]
35. The effects of inhaled formoterol on the autonomic nervous system in adolescents with asthma.
Sekerel BE; Sahiner UM; Can M; Abali G; Alehan D; Aytemir K
Ann Allergy Asthma Immunol; 2011 Sep; 107(3):266-72. PubMed ID: 21875547
[TBL] [Abstract][Full Text] [Related]
36. Stereoselective urinary excretion of formoterol and its glucuronide conjugate in human.
Zhang M; Fawcett JP; Shaw JP
Br J Clin Pharmacol; 2002 Sep; 54(3):246-50. PubMed ID: 12236843
[TBL] [Abstract][Full Text] [Related]
37. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients.
Dusser D; Vicaut E; Lefrançois G;
Respiration; 2005; 72 Suppl 1():20-7. PubMed ID: 15915009
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic and pharmacodynamic characteristics and safety of inhaled albuterol enantiomers in healthy volunteers.
Gumbhir-Shah K; Kellerman DJ; DeGraw S; Koch P; Jusko WJ
J Clin Pharmacol; 1998 Dec; 38(12):1096-106. PubMed ID: 11301561
[TBL] [Abstract][Full Text] [Related]
39. Patient-reported outcomes in adults with moderate to severe asthma after use of budesonide and formoterol administered via 1 pressurized metered-dose inhaler.
Chervinsky P; Baker J; Bensch G; Parasuraman B; Boggs R; Martin P; O'Dowd L
Ann Allergy Asthma Immunol; 2008 Nov; 101(5):463-73. PubMed ID: 19055199
[TBL] [Abstract][Full Text] [Related]
40. Biphasic effect-time courses in man after formoterol inhalation: eosinopenic and hypokalemic effects and inhibition of allergic skin reactions.
Derks MG; van den Berg BT; van der Zee JS; Braat MC; van Boxtel CJ
J Pharmacol Exp Ther; 1997 Nov; 283(2):824-32. PubMed ID: 9353404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
